US HB4398 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 1-0)
Status: Introduced on September 19 2019 - 25% progression, died in committee
Action: 2019-10-02 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Pending: House Subcommittee on Antitrust, Commercial, and Administrative Law Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on September 19 2019 - 25% progression, died in committee
Action: 2019-10-02 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Pending: House Subcommittee on Antitrust, Commercial, and Administrative Law Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.
Title
Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
Sponsors
| Rep. David Cicilline [D-RI] |
History
| Date | Chamber | Action |
|---|---|---|
| 2019-10-02 | House | Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. |
| 2019-09-19 | House | Referred to the House Committee on the Judiciary. |
| 2019-09-19 | House | Introduced in House |
Same As/Similar To
SB1416 (Related) 2019-06-28 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.
HB5133 (Related) 2020-12-24 - Placed on the Union Calendar, Calendar No. 578.
HB2486 (Related) 2020-07-23 - Message on House action received in Senate and at desk: House amendments to Senate amendment.
HB5133 (Related) 2020-12-24 - Placed on the Union Calendar, Calendar No. 578.
HB2486 (Related) 2020-07-23 - Message on House action received in Senate and at desk: House amendments to Senate amendment.
Subjects
Administrative remedies
Civil actions and liability
Commerce
Competition and antitrust
Consumer affairs
Drug safety, medical device, and laboratory regulation
Federal Trade Commission (FTC)
Health care costs and insurance
Inflation and prices
Intellectual property
Judicial review and appeals
Manufacturing
Prescription drugs
Civil actions and liability
Commerce
Competition and antitrust
Consumer affairs
Drug safety, medical device, and laboratory regulation
Federal Trade Commission (FTC)
Health care costs and insurance
Inflation and prices
Intellectual property
Judicial review and appeals
Manufacturing
Prescription drugs
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/house-bill/4398/all-info |
| Text | https://www.congress.gov/116/bills/hr4398/BILLS-116hr4398ih.pdf |
